clinicaltrialsarena5 小时
Corcept Therapeutics’ Cushing’s syndrome therapy shows promise in Phase III trial
Corcept Therapeutics has reported positive outcomes from its Phase III study of relacorilant, a treatment for endogenous hypercortisolism.